Sandoz Group AG (BST:D8Y0)
Germany · Delayed Price · Currency is EUR | Market Cap | 38.75B +67.3% |
| Revenue (ttm) | 10.22B +10.3% |
| Net Income | 565.44M +184.6% |
| EPS | 1.29 +180.8% |
| Shares Out | n/a |
| PE Ratio | 69.37 |
| Forward PE | 22.82 |
| Dividend | 0.52 (0.58%) |
| Ex-Dividend Date | Apr 14, 2026 |
| Volume | 30 |
| Open | 84.50 |
| Previous Close | 85.50 |
| Day's Range | 84.00 - 92.50 |
| 52-Week Range | 52.50 - 92.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden pat... [Read more]
News
Sandoz Shares Fall After Company Turns Cautious on Sales Guidance
Shares dropped after the company issued a more cautious outlook on top-line growth for 2026, citing challenging conditions in Germany and supply constraints for biosimilar drugs.
Sandoz Group AG Earnings Call Transcript: Q3 2026
Q3 sales grew 5%, or 7% excluding anti-infectives B2B, as biosimilars advanced 17%. FY26 sales guidance narrowed to 5%-6%, while core EBITDA margin guidance rose to 23.0%-23.5% amid temporary German market and supply pressures.
Sandoz Group AG Earnings release: Q3 2026
Sandoz Group AG released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Sandoz Group AG Slides: Q3 2026
Sandoz Group AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
Generic drugmaker Sandoz lowers sales outlook, lifts profit forecast
Swiss generic drugmaker Sandoz Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply constraints weighed on third-quar...
‘Why do we value a Mars bar more than life-saving medicine?’ Sandoz CEO calls for level playing field with cheap Chinese antibiotics
The Swiss pharmaceutical giant operates one of the last penicillin plants in Europe—losing it would raise new security and sovereignty challenges, says CEO Richard Saynor.
Sandoz Group AG - Depositary Receipt Consensus Price Target Raised 10.10% to $93.47
The average one-year price target for Sandoz Group AG - Depositary Receipt (OTCPK:SDZNY) (DB:D8Y0) has been revised to $93.47 / share. This is an increase of 10.10% from the prior estimate of $84.89 d...
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
NBIX vs. SDZNY: Which Stock Is the Better Value Option?
Sandoz price target raised to CHF 60 from CHF 55 at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Sandoz (SDZNY) to CHF 60 from CHF 55 and keeps an Underweight rating on the shares. Published first on…
mAbxience, Sandoz sign collaboration agreement for biosimilar access
mAbxience, a majority-owned company of Fresenius (FSNUY) with partial ownership from Insud Pharma; and Sandoz (SDZNY) announced a licensing, development, manufacturing and commercialization agreement ...
mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide
mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab bi...
Sandoz Gets Canada Approval for Generic Version of Ozempic
The approval for its generic version of diabetes drug Ozempic advances its efforts to build a portfolio of GLP-1 medicines.
Sandoz price target raised to CHF 72 from CHF 66 at Berenberg
Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 72 from CHF 66 and keeps a Hold rating on the shares.
'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat
Sandoz CEO Richard Saynor warned U.S. patients could ultimately bear the cost of threatened tariffs on imported generic drugs. Saynor said manufacturers facing steep tariffs could be forced to raise p...
Sandoz Group AG Transcript: CMD 2026
Bio 100 aims to deliver over 100 biosimilars by 2040, doubling net sales by 2035 and achieving a core EBITDA margin above 30%. Growth is driven by vertical integration, regulatory streamlining, and global commercial execution, with $2–2.5 billion in new investments supporting this ambition.
Sandoz Group AG Press release: FY 2026
Sandoz Group AG issued a press release on September 8, 2026, disclosing material business information to investors.
Sandoz Group AG Slides: FY 2026
Sandoz Group AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 8, 2026.
Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth
Sandoz aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its fo...
Sandoz initiated with a Buy at Erste Group
Erste Group analyst Hans Engel initiated coverage of Sandoz (SDZNY) with a Buy rating. The company’s product pipeline in the biosimilars segment is expanded and new markets will be tapped,…
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initi...
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech
Swiss generic drugmaker Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drug...
Sandoz price target raised to CHF 80 from CHF 75 at JPMorgan
JPMorgan raised the firm’s price target on Sandoz (SDZNY) to CHF 80 from CHF 75 and keeps an Overweight rating on the shares.
Sandoz Shares Climb After Biosimilar Sales Drive Growth
Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a return to growth in generics.
Sandoz Group AG Earnings Call Transcript: Q2 2026
Strong H1 2026 results driven by biosimilars, with 5% net sales growth and margin expansion. Regulatory milestones, new launches, and a robust pipeline underpin confidence in 2026 guidance and a positive outlook for 2027-2028.
Sandoz Group AG Slides: Q2 2026
Sandoz Group AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.